Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. / Schuster, H.; Fagerberg, B.; Edwards, S.; Halmos, T.; Lopatynski, J.; Stender, S.; Birketvedt, G.S.; Tonstad, S.; Gause-Nilsson, I.; Halldorsdottir, S.; Ohman, K.P.
In: Atherosclerosis, Vol. 197, No. 1, 2008, p. 355-362.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance
AU - Schuster, H.
AU - Fagerberg, B.
AU - Edwards, S.
AU - Halmos, T.
AU - Lopatynski, J.
AU - Stender, S.
AU - Birketvedt, G.S.
AU - Tonstad, S.
AU - Gause-Nilsson, I.
AU - Halldorsdottir, S.
AU - Ohman, K.P.
N1 - Times Cited: 1ArticleEnglishSchuster, HInfogen, Xantener Str 10, D-10707 Berlin, GermanyCited References Count: 32282LSELSEVIER IRELAND LTDELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDCLARE
PY - 2008
Y1 - 2008
N2 - Aim: To determine the effects of the peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist tesaglitazar on serum levels of apolipoprotein (apo) A-I, apoB, and apoCIII in non-diabetic insulin-resistant subjects. Methods: This randomized, double-blind, multicentre, placebo-controlled trial examined the effect of tesaglitazar (0.1, 0.25, 0.5, and 1 mg) once daily for 12 weeks on apolipoprotein levels in 390 abdominally obese subjects with hypertriglyceridaemia. Results: Tesaglitazar dose-dependently increased serum concentrations of apoA-I (p < 0.009) and decreased concentrations of apoB (p < 0.0001), the apoB/apoA-I ratio (p < 0.0001), and apoCIII (p < 0.0001). Similar improvements were observed in all subgroups of subjects, where individuals were grouped according to age, gender, baseline body mass index, serum triglycerides and high-density lipoprotein cholesterol levels. Low-density lipoprotein particle concentrations were also dose-dependently reduced by tesaglitazar (P < 0.0001). Conclusion: Although tesaglitazar is no longer in clinical development, these data indicate that dual PPAR alpha/gamma agonism may be a useful pharmacological approach to improve the atherogenic dyslipidaemia associated with insulin resistance. (C) 2007 Elsevier Ireland Ltd. All rights reserved Udgivelsesdato: 2008/3
AB - Aim: To determine the effects of the peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist tesaglitazar on serum levels of apolipoprotein (apo) A-I, apoB, and apoCIII in non-diabetic insulin-resistant subjects. Methods: This randomized, double-blind, multicentre, placebo-controlled trial examined the effect of tesaglitazar (0.1, 0.25, 0.5, and 1 mg) once daily for 12 weeks on apolipoprotein levels in 390 abdominally obese subjects with hypertriglyceridaemia. Results: Tesaglitazar dose-dependently increased serum concentrations of apoA-I (p < 0.009) and decreased concentrations of apoB (p < 0.0001), the apoB/apoA-I ratio (p < 0.0001), and apoCIII (p < 0.0001). Similar improvements were observed in all subgroups of subjects, where individuals were grouped according to age, gender, baseline body mass index, serum triglycerides and high-density lipoprotein cholesterol levels. Low-density lipoprotein particle concentrations were also dose-dependently reduced by tesaglitazar (P < 0.0001). Conclusion: Although tesaglitazar is no longer in clinical development, these data indicate that dual PPAR alpha/gamma agonism may be a useful pharmacological approach to improve the atherogenic dyslipidaemia associated with insulin resistance. (C) 2007 Elsevier Ireland Ltd. All rights reserved Udgivelsesdato: 2008/3
M3 - Journal article
VL - 197
SP - 355
EP - 362
JO - Atherosclerosis
JF - Atherosclerosis
SN - 0021-9150
IS - 1
ER -
ID: 10914236